Results 141 to 150 of about 38,400 (238)

Dietary Polyphenols as Natural Modulators of NF‐κB Signaling in Inflammation‐Driven Non‐Communicable Diseases: Focus on Cancer

open access: yesFood Science &Nutrition, Volume 14, Issue 7, July 2026.
Dietary polyphenols and phytochemicals suppress NF‐κB signaling. Mechanistically, by inhibiting IκBα degradation and preventing nuclear translocation of p65/p50 complexes, the polyphenols reduce the expression of pro‐inflammatory and pro‐survival genes, thereby decreasing overall cancer cell survival.
Khuzin Dinislam   +3 more
wiley   +1 more source

Inflammatory signatures in the spectrum of myeloid diseases

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract Dysregulated innate immunity contributes to clonal cytopenias and myeloid neoplasms, but its extent across disease stages and clinical relevance remain incompletely defined. We analyzed plasma ASC/NLRP3 double‐positive (DP) specks, ASC single‐positive (SP) specks, and 45 cytokines in 223 patients with idiopathic cytopenias of undetermined ...
Alice Ibbotson   +12 more
wiley   +1 more source

Autoimmunity and peginterferon therapy for polycythemia vera

open access: yesHemaSphere, Volume 10, Issue 7, July 2026.
Abstract Peginterferon‑α is useful to treat myeloproliferative neoplasms (MPNs) but can precipitate broad autoimmunity. By promoting beta‐cell, thyroid, and systemic immune injury, it can lead to Type 1 diabetes, autoimmune thyroiditis, systemic lupus erythematosus, or Sjögren's syndrome.
Etienne Rivière   +8 more
wiley   +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang   +9 more
wiley   +1 more source

Ischemia–Reperfusion Injury: Molecular Mechanisms and Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Multiorgan ischemia–reperfusion injury begins with ischemia‐induced ATP depletion and ionic imbalance, followed by reperfusion‐triggered mitochondrial ROS/RNS bursts, regulated cell death, and DAMP release. Sterile inflammation converges on endothelial–immune–coagulation crosstalk, where NETs drive immunothrombosis, no‐reflow, and remote organ injury ...
Peng An   +4 more
wiley   +1 more source

Plasmacytoid dendritic cells modulate the production of mucosal IgA in IgA nephropathy. [PDF]

open access: yesNephrol Dial Transplant
Fukao Y   +9 more
europepmc   +1 more source

Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Extracellular vesicles play a crucial role in interorgan crosstalk of adipose–liver and gut–liver axes and hold potential as therapeutic targets and drug delivery systems for metabolic dysfunction‐associated fatty liver disease (MAFLD). Abbreviations: AT: adipose tissue; EVs: extracellular vesicles; HL: healthy liver; NAFL: nonalcoholic fatty liver ...
Zhifu Cui   +5 more
wiley   +1 more source

Preparation of a multiepitope vaccine candidate for camel bocavirus and evaluation of its immunogenicity in a mouse model. [PDF]

open access: yesFront Immunol
Tao X   +14 more
europepmc   +1 more source

CD8+ Tissue‐Resident Memory T Cells in Health and Disease

open access: yesMedComm, Volume 7, Issue 7, July 2026.
CD8+ TRM cells are at the center of immunity, mediating potent local innate and adaptive immune responses. While TRM cells mediate protective immunity against infections and tumors, they also contribute to pathological inflammation in autoimmune conditions.
Yu‐Han Ai   +13 more
wiley   +1 more source

PSCA-directed nanosized bio-immune conjugates (NANO:BICs) enable selective uptake of TLR9 agonists in bladder cancer cells. [PDF]

open access: yesFront Oncol
Iltzsche M   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy